<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054625</url>
  </required_header>
  <id_info>
    <org_study_id>GEN211</org_study_id>
    <nct_id>NCT01054625</nct_id>
  </id_info>
  <brief_title>Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)</brief_title>
  <official_title>An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to support current and future Zalutumumab studies by increasing the
      Pharmacokinetic (PK) knowledge of the drug. PK is the study of how a drug is absorbed (taken
      up), distributed (moved around), metabolised (broken down) and excreted (removed) by the
      body, in relation to time. The first PK trial only went up to 8 mg/kg, and, as there has been
      some indication that the PK profile for the higher and lower doses is different, this needs
      to be further evaluated. Furthermore, there is a need for more PK data on dosing with
      16mg/kg.

      The aim with this study is therefore to evaluate the PK profiles at different doses of
      Zalutumumab and the amount of drug in the blood at different time points after single and
      multiple doses. The results of this study, combined with data from completed and ongoing
      Zalutumumab studies, will enable us to provide patients with an effective treatment option
      which may significantly prolong their survival and/or improve their quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to look at the Pharmacokinetics (PK) of Zalutumumab in patients with Head and
      Neck Cancer. 26 participants will be treated with the study drug Zalutumumab at 4 different
      doses. Zalutumumab will be given at day 0, day 14, day 21 and day 28. Blood samples (for PK
      and to check the participant's safety) will be taken before drug is given. Blood samples for
      PK only will be taken directly after drug is given at all treatment visits and also at +3hr
      and +12hrs on day 0 and day 28 which may require an overnight stay.

      Blood samples for PK only are also taken on days between treatments. After treatment on day
      28, eight more blood samples will be taken over 3 weeks. On day 49 participants may enter an
      optional extended treatment period receiving the drug weekly until it is no longer
      appropriate for the participant (doctor/participant decision or cancer has advanced).

      Dosing in the extended treatment period will start at 16mg/kg. The correct dose for the
      participant will be checked at each visit by looking for the presence and severity of skin
      rash. This is a common side effect of medicines like Zalutumumab which block the Epidermal
      Growth Factor Receptor. The severity of the skin rash is used as a guide for dosing. A mild
      rash could mean more medication is needed, a severe rash will mean the participant needs a
      break from the medication. End of study is 8 weeks after the last dose of Zalutumumab and
      blood samples will be taken +4weeks and +8weeks after the last dose of drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration of Zalutumumab After Fourth Infusion</measure>
    <time_frame>Pre and post infusion after weekly administration of zalutumumab during 28 days</time_frame>
    <description>PK samples are taken: pre and post infusion on days 0, 14, 21 and 28 plus at +3 and +12 hours on days 0 and 28. A single PK sample is taken on days between these treatments and 8 more are taken over 3 weeks after treatment on day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve 0-7 Days</measure>
    <time_frame>0-7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve 0-21 Days</measure>
    <time_frame>0-21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady State</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>zalutumumab 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zalutumumab 4 mg/kg iv single infusion week 1,3, 4 and 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zalutumumab 8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zalutumumab 8 mg/kg iv single infusion week 1, 3, 4 and 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zalutumumab 16 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zalutumumab 16 mg/kg iv single infusion week 1, 3, 4 and 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>zalutumumab</intervention_name>
    <description>Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.</description>
    <arm_group_label>zalutumumab 4 mg/kg</arm_group_label>
    <arm_group_label>zalutumumab 8 mg/kg</arm_group_label>
    <arm_group_label>zalutumumab 16 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ≥ 18 years.

          -  Diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or
             larynx, considered incurable with standard therapy. Diagnosis will have been confirmed
             using a biopsy of the tumour.

          -  Patients having, based on the investigators judgment, had disease progression and for
             whom curative therapy is not possible.

          -  Patients with a WHO performance status ≤ 2 and a life expectancy of greater than 3
             months.

          -  Following receipt of verbal and written information about the study, the patient must
             provide signed informed consent before any study related activity is carried out.

        Exclusion Criteria:

          -  Patients previously treated with any Epidermal Growth Factor Receptor (EGFR) targeted
             therapy such as anti-EGFR monoclonal antibodies or small molecule inhibitors within 6
             months prior to visit 2 (first treatment).

          -  Received the following treatments within 4 weeks prior to Visit 2 (first treatment):

               -  Cytotoxic or cytostatic anticancer chemotherapy

               -  Total tumor resection

               -  Radiotherapy of &gt; 50 Gy to gross tumor volume

          -  Chronic or current infectious disease such as, but not limited to, chronic renal
             infection, chronic chest infection with bronchiectasis, sinusitis, and tuberculosis

          -  Clinically significant cardiac disease including unstable angina, acute myocardial
             infarction within six months from Visit 1 (screening), congestive heart failure, and
             arrhythmia requiring therapy, with the exception of extra systoles or minor conduction
             abnormalities

          -  Significant concurrent, uncontrolled medical condition including, but not limited to,
             renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological,
             cerebral or psychiatric disease

          -  History of significant cerebrovascular disease

          -  Known HIV infection

          -  Known hepatitis B and/or hepatitis C

          -  Screening laboratory values:

               -  Neutrophils &lt; 1.5 x109/l

               -  Platelets &lt; 75 x109/l

               -  ALAT &gt; 2.5 times the upper limit of normal (unless known liver metastases
                  exceptions will be dealt with on a case by case basis)

               -  ALP &gt; 2.5 times the upper limit of normal (unless known liver metastases
                  exceptions will be dealt with on a case by case basis)

               -  Bilirubin &gt; 1.5 times the upper limit of normal

               -  Creatinine clearance &lt; 50 ml/min (measured or calculated by the CockgroftGault
                  method)

          -  Patients who have received treatment with any non-marketed drug substance within 4
             weeks before Visit 1(screening)

          -  Current participation in any other interventional clinical study

          -  Patients with a BMI ≥ 30 kg/m2

          -  Patients known or suspected of not being able to comply with a study protocol (e.g.
             due to alcoholism, drug dependency or psychological disorder)

          -  Breast feeding women or women with a positive pregnancy test at Visit 1 (screening)

          -  Women of childbearing potential not willing to use adequate contraception such as
             hormonal birth control or intrauterine device during study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pascal Machiels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires SaintLuc, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires SaintLuc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uz Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>H-1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vas Megye es Szombathely</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny onkologicky ustav</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Tnava</name>
      <address>
        <city>Trnava</city>
        <zip>917 75</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Institute of Oncology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>August 8, 2013</results_first_submitted>
  <results_first_submitted_qc>November 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 3, 2014</results_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma of the Head and Neck</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>anti-EGFr monoclonal antibody</keyword>
  <keyword>Zalutumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zalutumumab 4 mg/kg</title>
          <description>zalutumumab 4 mg/kg iv infusion</description>
        </group>
        <group group_id="P2">
          <title>Zalutumumab 8 mg/kg</title>
          <description>zalutumumab 8 mg/kg iv infusion</description>
        </group>
        <group group_id="P3">
          <title>Zalutumumab 16 mg/kg</title>
          <description>zalutumumab 16 mg/kg iv infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">A total of 31 patients were enrolled, 1 patient died before receiving any zalutumumab</participants>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Thirty of the 31 enrolled patients were included in the full analysis set (FAS) population. One patient was excluded from the FAS because he died before the first infusion of trial drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Zalutumumab 4 mg/kg</title>
          <description>zalutumumab 4 mg/kg iv infusion</description>
        </group>
        <group group_id="B2">
          <title>Zalutumumab 8 mg/kg</title>
          <description>zalutumumab 8 mg/kg iv infusion</description>
        </group>
        <group group_id="B3">
          <title>Zalutumumab 16 mg/kg</title>
          <description>zalutumumab 16 mg/kg iv infusion</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="8"/>
                    <measurement group_id="B2" value="63" spread="11"/>
                    <measurement group_id="B3" value="59" spread="5"/>
                    <measurement group_id="B4" value="60" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration of Zalutumumab After Fourth Infusion</title>
        <description>PK samples are taken: pre and post infusion on days 0, 14, 21 and 28 plus at +3 and +12 hours on days 0 and 28. A single PK sample is taken on days between these treatments and 8 more are taken over 3 weeks after treatment on day 28.</description>
        <time_frame>Pre and post infusion after weekly administration of zalutumumab during 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zalutumumab 4 mg/kg</title>
            <description>zalutumumab 4 mg/kg iv infusion</description>
          </group>
          <group group_id="O2">
            <title>Zalutumumab 8 mg/kg</title>
            <description>zalutumumab 8 mg/kg iv infusion</description>
          </group>
          <group group_id="O3">
            <title>Zalutumumab 16 mg/kg</title>
            <description>zalutumumab 16 mg/kg iv infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration of Zalutumumab After Fourth Infusion</title>
          <description>PK samples are taken: pre and post infusion on days 0, 14, 21 and 28 plus at +3 and +12 hours on days 0 and 28. A single PK sample is taken on days between these treatments and 8 more are taken over 3 weeks after treatment on day 28.</description>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.3" spread="31"/>
                    <measurement group_id="O2" value="258.1" spread="28"/>
                    <measurement group_id="O3" value="494.3" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve 0-7 Days</title>
        <time_frame>0-7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zalutumumab 4 mg/kg</title>
            <description>zalutumumab 4 mg/kg iv infusion</description>
          </group>
          <group group_id="O2">
            <title>Zalutumumab 8 mg/kg</title>
            <description>zalutumumab 8 mg/kg iv infusion</description>
          </group>
          <group group_id="O3">
            <title>Zalutumumab 16 mg/kg</title>
            <description>zalutumumab 16 mg/kg iv infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve 0-7 Days</title>
          <units>h mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9308" spread="47"/>
                    <measurement group_id="O2" value="25091" spread="36"/>
                    <measurement group_id="O3" value="52158" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve 0-21 Days</title>
        <time_frame>0-21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zalutumumab 4 mg/kg</title>
            <description>zalutumumab 4 mg/kg iv infusion</description>
          </group>
          <group group_id="O2">
            <title>Zalutumumab 8 mg/kg</title>
            <description>zalutumumab 8 mg/kg iv infusion</description>
          </group>
          <group group_id="O3">
            <title>Zalutumumab 16 mg/kg</title>
            <description>zalutumumab 16 mg/kg iv infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve 0-21 Days</title>
          <units>h mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12728" spread="61"/>
                    <measurement group_id="O2" value="44275" spread="43"/>
                    <measurement group_id="O3" value="105960" spread="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-life</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zalutumumab 4 mg/kg</title>
            <description>zalutumumab 4 mg/kg iv infusion</description>
          </group>
          <group group_id="O2">
            <title>Zalutumumab 8 mg/kg</title>
            <description>zalutumumab 8 mg/kg iv infusion</description>
          </group>
          <group group_id="O3">
            <title>Zalutumumab 16 mg/kg</title>
            <description>zalutumumab 16 mg/kg iv infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="72"/>
                    <measurement group_id="O2" value="192.8" spread="38"/>
                    <measurement group_id="O3" value="283.0" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zalutumumab 4 mg/kg</title>
            <description>zalutumumab 4 mg/kg iv infusion</description>
          </group>
          <group group_id="O2">
            <title>Zalutumumab 8 mg/kg</title>
            <description>zalutumumab 8 mg/kg iv infusion</description>
          </group>
          <group group_id="O3">
            <title>Zalutumumab 16 mg/kg</title>
            <description>zalutumumab 16 mg/kg iv infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance</title>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="56"/>
                    <measurement group_id="O2" value="0.018" spread="26"/>
                    <measurement group_id="O3" value="0.019" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zalutumumab 4 mg/kg</title>
            <description>zalutumumab 4 mg/kg iv infusion</description>
          </group>
          <group group_id="O2">
            <title>Zalutumumab 8 mg/kg</title>
            <description>zalutumumab 8 mg/kg iv infusion</description>
          </group>
          <group group_id="O3">
            <title>Zalutumumab 16 mg/kg</title>
            <description>zalutumumab 16 mg/kg iv infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase</title>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="49"/>
                    <measurement group_id="O2" value="4.99" spread="35"/>
                    <measurement group_id="O3" value="7.83" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution at Steady State</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zalutumumab 4 mg/kg</title>
            <description>zalutumumab 4 mg/kg iv infusion</description>
          </group>
          <group group_id="O2">
            <title>Zalutumumab 8 mg/kg</title>
            <description>zalutumumab 8 mg/kg iv infusion</description>
          </group>
          <group group_id="O3">
            <title>Zalutumumab 16 mg/kg</title>
            <description>zalutumumab 16 mg/kg iv infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution at Steady State</title>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="27"/>
                    <measurement group_id="O2" value="4.86" spread="29"/>
                    <measurement group_id="O3" value="7.72" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at weekly visits during the treatment period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Zalutumumab 4 mg/kg</title>
          <description>zalutumumab 4 mg/kg iv infusion</description>
        </group>
        <group group_id="E2">
          <title>Zalutumumab 8 mg/kg</title>
          <description>zalutumumab 8 mg/kg iv infusion</description>
        </group>
        <group group_id="E3">
          <title>Zalutumumab 16 mg/kg</title>
          <description>zalutumumab 16 mg/kg iv infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The site and the PI may be required to withhold the publication for up to 90 days. Subject to a reasoned request from the sponsor, the publication may be further delayed for a period up to 6 months from the date of first submission to the sponsor.
The sponsor has the right to require deletion of any trade secret, proprietary, or confidential information supplied by the sponsor to the site or the PI. The sponsor shall not otherwise have the right to censor publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eva Järlid Westerberg, VP Clinical Operations</name_or_title>
      <organization>Genmab A/S</organization>
      <phone>+45 7020 2728</phone>
      <email>E.Westerberg@genmab.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

